Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vanza CF triplet achieved non-inferiority compared to TRIKAFTA in lung function measure and achieved statistically significant improvement in sweat chloride levels compared to it. Regulatory applications of Vanza triplet to the FDA and EMA to treat CF patients ages 6 and older with the F508del mutation or responsive to CFTR modulator therapy, expected mid-2024. A Priority Review Voucher will be used for Vanza with respect to the FDA filing, so that it could obtain a shorter review period for possible U.S. marketing approval.

Vertex: Vanza Triplet Data Allows For Mid-2024 Regulatory Submissions

Vertex's (VRTX) fourth-quarter earnings and revenues surpass estimates. The company reports encouraging data on triple combination of vanzacaftor studies.

Vertex's (VRTX) Q4 Earnings and Sales Surpass Estimates

Vertex Pharmaceuticals' pain relief program could be lucrative in the years ahead. Phase 3 clinical trials suggest the current medicine is likely to be approved for sale.

Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can Invest

GlaxoSmithKline

Intuitive Surgical

Johnson & Johnson

Medtronic

Pfizer

Teladoc

Healthcare stocks in 2024 are charting an impressive course, emerging as formidable contenders in the investment sphere. After weathering a challenging 2023, these stocks are on the rise, with the S&P 500 Health Care index showcasing an almost 11% rise in the last three months alone.

The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024

Vertex Pharmaceuticals' acute pain candidate was not as impressive as hoped in a late-stage study. Still, the drugmaker has an excellent lineup and multiple highly promising pipeline candidates.

This High-Flying Stock Just Got Some Bad News: Should You Sell?

Vertex Pharmaceuticals Incorporated (VRTX) Q4 2023 Earnings Call Transcript

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.20 per share, beating the Zacks Consensus Estimate of $4.10 per share. This compares to earnings of $3.76 per share a year ago.

Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates

Vertex topped fourth-quarter expectations and reported positive results for its next-generation cystic fibrosis drug. VRTX stock rose.

Vertex's Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly Beat

Vertex Pharmaceuticals experimental triple combination cystic fibrosis (CF) treatment met all late-stage study goals when tested in patients aged 12 years and older, the company said on Monday.

Vertex's triple combination CF drug meets main late-stage trial goals

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2023 and provided full year 2024 financial guidance. “2023 was a transformative year for Vertex as we continued our strong performance, including 11% revenue growth, combined with significant advancement across the business. We expanded our leadership in CF, diversified our commercial opportunity with CASGEVY regulatory.

Vertex Reports Fourth Quarter and Full Year 2023 Financial Results

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its once-daily vanzacaftor/tezacaftor/deutivacaftor (the “vanza triple”) program, the most comprehensive Phase 3 pivotal program ever conducted by Vertex for the treatment of cystic fibrosis (CF), a progressive, multi-organ disease caused by dysfunction of the CFTR protein. The Phase 3 program included two randomized, double-blind, active-controlled, 52-week trials, SKYLINE 102 and.

Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis

Vertex's cystic fibrosis portfolio has been a raging success for the company. The biotech's next potential product addresses the extremely common problem of pain -- and could become its next blockbuster.

Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?

CRISPR Therapeutics

Illumina

Healthcare stocks are one part of the stock market that has a lot of room to grow until 2024. The healthcare industry is growing because of the growing focus on health and well-being around the world.

Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements

StoneCo

Thermo Fisher Scientific

An investment sweet spot is often informally defined as the ideal entry point for buying based on recent macroeconomic developments. Technically, it's a price entry point that guarantees maximum profits or a high probability of a successful reversal trade.

Buy Alert: 3 Stocks Sitting in the Sweet Spot

Three late-stage studies data show that Vertex's (VRTX) experimental non-opioid drug reduced pain across a 48-hour period. Based on this data, VRTX intends to submit an FDA filing by mid-2024.

Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal

Beyond analysts' top -and-bottom-line estimates for Vertex (VRTX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Stay Ahead of the Game With Vertex (VRTX) Q4 Earnings: Wall Street's Insights on Key Metrics

The big biotech might just have a winner on its hands with an investigational pain treatment. VX-548 performed well in late-stage clinical testing, although there were some caveats.

Why Vertex Pharmaceuticals Stock Topped the Market Today

The trial results bring the biotech company one step closer to developing a drug that can provide strong pain relief without the addictive potential of opioids.

Vertex non-opioid painkiller shows positive results in critical late-stage trial on acute pain

The non-opioid drug from Vertex Pharmaceuticals lowered the pain of study subjects, though it didn't work better than popular painkiller Vicodin.

New Drug Shown to Relieve Pain Without Getting Patients Addicted

Vertex's alternative to opioids is "not a game-changer," an analyst said Tuesday as VRTX stock slipped on the company's Phase 3 test results.

Vertex Skids — Its Alternative To Opioids Is 'Not A Game-Changer,' Says Analyst

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain. The Phase 3 program included two randomized, double-blind, placebo-controlled, pivotal trials, one following abdominoplasty surgery and one following bunionectomy surgery, as well as a single arm safety and effectiveness study which enrolled patients with a broad range.

Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals (VRTX) closed at $435.82 in the latest trading session, marking a +1.31% move from the prior day.

Vertex Pharmaceuticals (VRTX) Laps the Stock Market: Here's Why

AstraZeneca

Regeneron Pharmaceuticals

AstraZeneca appears to be an underrated growth stock. Regeneron Pharmaceuticals stands out as a perpetual market leader.

3 Magnificent Stocks to Buy and Hold Forever

Vertex Pharmaceuticals' work in cystic fibrosis isn't done yet. The company also stands to make headway in other areas over time.

Where Will Vertex Pharmaceuticals Be in 10 Years?

Sarepta Therapeutics

Sarepta Therapeutics and Vertex Pharmaceuticals both go after rare diseases. Sarepta has made headway in its core area, but there is more work to be done.

News for Vertex Pharmaceuticals Stock (VRTX)